Peak Pharmaceuticals, Inc. (PKPH) financial statements (2021 and earlier)

Company profile

Business Address 14201 N. HAYDEN ROAD, SUITE A-1
SCOTTSDALE, AZ 85260
State of Incorp. NV
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2017
9/30/2016
9/30/2015
9/30/2014
9/30/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments31 4515
Cash and cash equivalents31 4515
Disposal group, including discontinued operation  50  
Intangible current assets  1830
Other undisclosed current assets  191(23) 
Total current assets:312594585
Noncurrent Assets
Intangible assets, net (including goodwill)35351(35)
Intangible assets, net (excluding goodwill)35351(35) 
Other undisclosed noncurrent assets(35)(35)2168 
Total noncurrent assets:  2233 
TOTAL ASSETS:312814915
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities171 103  
Accounts payable163    
Accrued liabilities8    
Interest and dividends payable  103  
Debt25 603603 
Due to related parties 48274535
Disposal group, including discontinued operation  195  
Other undisclosed current liabilities 95(639)(594)10
Total current liabilities:1961432895444
Noncurrent Liabilities
Total liabilities:1961432895444
Stockholders' equity
Stockholders' equity attributable to parent, including:(193)(141)(7)436(39)
Common stock888822
Additional paid in capital4,8564,8566,1524,28839
Retained earnings (accumulated deficit)(5,056)(5,005)(6,167)(3,859)100
Other undisclosed stockholders' equity attributable to parent    (200)
Other undisclosed stockholders' equity    (0)
Total stockholders' equity:(193)(141)(7)436(39)
Other undisclosed liabilities and equity    0
TOTAL LIABILITIES AND EQUITY:312814915

Income statement (P&L) ($ in thousands)

9/30/2017
9/30/2016
9/30/2015
9/30/2014
9/30/2013
Gross profit:  (116)  
Operating expenses(45)1,088(2,339)(2,675)(12)
Other operating expense, net  (2)(672) 
Operating income (loss):(45)1,088(2,457)(3,347)(12)
Nonoperating income
(Debt Instrument, Convertible, Beneficial Conversion Feature)
   650 
Interest and debt expense(1) 2746 
Income (loss) from continuing operations before income taxes:(46)1,088(2,455)(1,951)(12)
Income tax benefit  1703825
Other undisclosed loss from continuing operations  (56)  
Income (loss) from continuing operations:(46)1,088(2,341)(1,569)(7)
Income from discontinued operations 7533  
Income (loss) before gain (loss) on sale of properties:(46)1,162(2,308)(1,569)(7)
Other undisclosed net loss    (5)
Net income (loss):(46)1,162(2,308)(1,569)(12)
Net income attributable to noncontrolling interest    12
Other undisclosed net loss attributable to parent(5)  (2,190)(12)
Net income (loss) available to common stockholders, diluted:(51)1,162(2,308)(3,759)(12)

Comprehensive Income ($ in thousands)

9/30/2017
9/30/2016
9/30/2015
9/30/2014
9/30/2013
Net income (loss):(46)1,162(2,308)(1,569)(12)
Comprehensive income (loss):(46)1,162(2,308)(1,569)(12)
Comprehensive loss, net of tax, attributable to noncontrolling interest    (12)
Comprehensive income (loss), net of tax, attributable to parent:(46)1,162(2,308)(1,569)(25)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: